{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:29:38Z","timestamp":1789532978942,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jtha.2024.10.034","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:14:53Z","timestamp":1731687293000},"page":"704-716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-1627","authenticated-orcid":false,"given":"Juri Alessandro","family":"Giannotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Artoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Agosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Carpenedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addolorata","family":"Truma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syna","family":"Miri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualina","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prassede","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Molteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermina","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasanta","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Prezioso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarosa","family":"Cuccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Massaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.10.034_bib1","doi-asserted-by":"crossref","first-page":"41059","DOI":"10.1074\/jbc.C100515200","article-title":"Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura","volume":"276","author":"Zheng","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.10.034_bib2","first-page":"536","article-title":"Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management","volume":"10","author":"Sukumar","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.10.034_bib3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.10.034_bib4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2141.2010.08385.x","article-title":"Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura","volume":"151","author":"Lotta","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.10.034_bib5","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.034_bib6","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2019.226423","article-title":"Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura","volume":"105","author":"Riva","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.10.034_bib7","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1182\/bloodadvances.2020004169","article-title":"Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission","volume":"6","author":"Sukumar","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.10.034_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.10.034_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.10.034_bib10","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.034_bib11","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.034_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A\u00a0regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.034_bib13","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A\u00a0phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.034_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.034_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.034_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221112217","article-title":"Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase","volume":"13","author":"Westwood","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2024.10.034_bib17","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/bjh.17170","article-title":"Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment","volume":"192","author":"Barba","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.10.034_bib18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/ajh.21281","article-title":"Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura","volume":"83","author":"Cataland","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.10.034_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-208477","article-title":"Thrombotic thrombocytopenic purpura as an initial presentation of systemic lupus erythematosus with acquired ADAMTS 13 antibody","volume":"2015","author":"Changcharoen","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jtha.2024.10.034_bib20","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/bloodadvances.2017009308","article-title":"Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura","volume":"1","author":"Cataland","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.10.034_bib21","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/bloodadvances.2022007632","article-title":"Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura","volume":"6","author":"Bichard","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.10.034_bib22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2024.10.034_bib23","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.10.034_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211046428","article-title":"Bortezomib in autoimmune hemolytic anemia and beyond","volume":"12","author":"Pasquale","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2024.10.034_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"68","author":"Shortt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.10.034_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28818","article-title":"Bortezomib induces long-term remission in children with immune thrombotic thrombocytopenic purpura, refractory to plasma exchange, glucocorticoids, and rituximab: a report on two cases","volume":"68","author":"Maschan","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtha.2024.10.034_bib27","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1097\/MPH.0000000000002026","article-title":"Successful treatment with bortezomib for refractory and complicated acquired thrombotic thrombocytopenic purpura in an adolescent girl","volume":"43","author":"Azapagasi","year":"2021","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtha.2024.10.034_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tmrv.2022.09.001","article-title":"Plasma cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP)","volume":"36","author":"Chen","year":"2022","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jtha.2024.10.034_bib29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.10.034_bib30","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjh.19035","article-title":"Bortezomib in relapsed\/refractory immune thrombotic thrombocytopenic purpura: a single-centre retrospective cohort and systematic literature review","volume":"204","author":"Lee","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.10.034_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.10.034_bib32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.034_bib34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fimmu.2013.00494","article-title":"Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy","volume":"4","author":"Mah\u00e9vas","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2024.10.034_bib35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B\u00a0cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.10.034_bib36","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura","volume":"130","author":"Kappers-Klunne","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.10.034_bib37","first-page":"349","article-title":"Case series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura","volume":"53","author":"Dubois","year":"2010","journal-title":"Can J Surg"},{"key":"10.1016\/j.jtha.2024.10.034_bib38","first-page":"3773","article-title":"Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives","volume":"10","author":"Treppo","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.10.034_bib39","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s10787-021-00863-2","article-title":"Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases","volume":"29","author":"Khalesi","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.jtha.2024.10.034_bib40","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma","volume":"96","author":"Lamm","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.10.034_bib41","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtha.2024.10.034_bib42","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenstr\u00f6m's macroglobulinemia: a prospectively randomized trial of the European Consortium for Waldenstr\u00f6m's Macroglobulinemia","volume":"41","author":"Buske","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2024.10.034_bib43","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028679","article-title":"Combination of low-dose rituximab, bortezomib, and dexamethasone for the treatment of autoimmune hemolytic anemia","volume":"101","author":"Yao","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtha.2024.10.034_bib44","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2022-166513","article-title":"Rituximab and bortezomib for patients with newly diagnosed acquired haemophilia: single arm, single center, prospective phase 2 study","volume":"140","author":"Cai","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.034_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.10.034_bib46","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.10.034_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2024.10.034_bib48","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/trf.12614","article-title":"Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report","volume":"54","author":"Yates","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2024.10.034_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215491","article-title":"Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura","volume":"2016","author":"Acedillo","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jtha.2024.10.034_bib50","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3390\/cancers12092540","article-title":"Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects","volume":"12","author":"Pancheri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtha.2024.10.034_bib51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/hon.2706","article-title":"Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase III trials","volume":"38","author":"Li","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jtha.2024.10.034_bib52","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.034_bib53","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura","volume":"6","author":"Izquierdo","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.10.034_bib54","first-page":"209","article-title":"Prolonged exposure to caplacizumab as rescue therapy in refractory immune thrombotic thrombocytopenic purpura","volume":"14","author":"Rodgers","year":"2023","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2024.10.034_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102185","article-title":"Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry","volume":"7","author":"Agosti","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.034_bib56","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/jth.15045","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab","volume":"18","author":"V\u00f6lker","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.034_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103661","article-title":"Therapeutic plasma exchange-free treatment for first-episode TTP: a systematic review","volume":"62","author":"Wang","year":"2023","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtha.2024.10.034_bib58","first-page":"2206","article-title":"Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era","volume":"141","author":"Prasannan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.034_bib59","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood.2023022725","article-title":"ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy","volume":"143","author":"Mingot-Castellano","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.034_bib60","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2015-05-643338","article-title":"Low ADAMTS13 activity is associated with an increased risk of ischemic stroke","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.034_bib61","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.034_bib62","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/bloodadvances.2021005124","article-title":"Daratumumab for immune thrombotic thrombocytopenic purpura","volume":"6","author":"van den Berg","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.10.034_bib63","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.18854","article-title":"Daratumumab for refractory immune-mediated thrombotic thrombocytopenic purpura","volume":"202","author":"Aggarwal","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.10.034_bib64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11239-023-02768-z","article-title":"Combination regimens containing daratumumab for initial diagnosed acquired thrombotic thrombocytopenic purpura","volume":"55","author":"Xie","year":"2023","journal-title":"J\u00a0Thromb Thrombolysis"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400686X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400686X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:11:33Z","timestamp":1762549893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362400686X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S153878362400686X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.10.034","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}